Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.
about
Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirusNeuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for interventionThe evolution of poxvirus vaccinesModified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesDual neonate vaccine platform against HIV-1 and M. tuberculosis.Prevention of maternal cytomegalovirus infection: current status and future prospects.Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccineA vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection agaUpdate on the current status of cytomegalovirus vaccines.A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.Vaccine strategies against human cytomegalovirus infection.A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models.DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.Boosting with recombinant MVA expressing M. tuberculosis α-crystallin antigen augments the protection imparted by BCG against tuberculosis in guinea pigs.
P2860
Q21092179-A6A67571-FDA0-4511-B166-C0732D537F87Q24570124-230669DF-5432-4FD1-8C77-01ECF3F1B296Q26995905-9FFFA908-CF85-4AFF-A417-1983FC988678Q33653229-C2F4C51C-984A-45F4-94A8-CB7E1798A747Q33908584-E7FF1700-FBBB-491D-ADBE-395BA46AD38EQ34272089-B0B52A35-AB76-429D-BC60-030FB32F1E01Q34349745-1943B109-7F01-4086-A546-FFC1982CFA1CQ34788895-BA8A0006-905F-4495-A8D8-4DEDDB1A13EEQ36559845-28837180-DA1A-48BC-9D86-85250D79017DQ36633558-D8894950-142E-4A6E-87F9-2E185A8F8975Q36678423-6F53ED2A-E611-47EC-8BD3-D288B2BD64B8Q36824066-9EBF18DF-3544-4774-824A-84DEEE497FE0Q36839736-ACA6AFCB-7346-4137-A435-BB7A1F166883Q36960608-60525078-9103-4E8D-83B9-348140ACFB81Q37530479-889EEA53-B773-444E-9BC6-89E0BF904437Q37559627-5A7944C8-2F62-4A7F-B7BE-883B4391A34CQ39703820-FB0712A1-1570-41C9-BA6C-04676BB917F1Q47155139-CD6C94D1-3567-48DD-B92B-ED38B5F5BE6E
P2860
Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Vaccine properties of a novel ...... ant CMV antigens pp65 and IE1.
@ast
Vaccine properties of a novel ...... ant CMV antigens pp65 and IE1.
@en
type
label
Vaccine properties of a novel ...... ant CMV antigens pp65 and IE1.
@ast
Vaccine properties of a novel ...... ant CMV antigens pp65 and IE1.
@en
prefLabel
Vaccine properties of a novel ...... ant CMV antigens pp65 and IE1.
@ast
Vaccine properties of a novel ...... ant CMV antigens pp65 and IE1.
@en
P2093
P2860
P1433
P1476
Vaccine properties of a novel ...... nant CMV antigens pp65 and IE1
@en
P2093
Aparna Krishnan
Corinna La Rosa
Joy Martinez
William J Britt
Zhongde Wang
Zhongqi Li
P2860
P304
P356
10.1016/J.VACCINE.2006.09.067
P407
P577
2006-10-06T00:00:00Z